ClinicalTrials.gg
CompletedNCT00290043Updated Dec 6, 2010

Glulisine Pre- and Postmeal

A Phase 1 interventional study of Insulin glulisine in Diabetes Mellitus Type 1, sponsored by Sanofi. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-12-06.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 1.

Enrollment
22nd of 25
20 · median 72
Started
2001
the only one that year
Phase 1
4 of 26
none open now
Registered
4th of 26
by date
Lead sponsor
15 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2001, is one of 4 in phase 1, and was the 4th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

To investigate in type 1 diabetic patients the glucodynamic response to HMR1964 insulin and RHI (HOE31HPR100) injected subcutaneously before and after a standard meal

03

Conditions studied

  • Diabetes Mellitus Type 1

Keywords

  • Insulin glulisine
  • Diabetes mellitus Type 1
  • Postprandial Period
  • Pharmacokinetics
  • Glucodynamics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Type 1 diabetes mellitus

Exclusion criteria

Exclusion Criteria:

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Outcome measures: Post-prandial glucose and insulin concentrations. Outcome: In T1DM, insulin glulisine provides a better mimic of the physiological postprandial glucose disposal than RHI.

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2001 and a completion of Mar 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2006
First posted
Feb 10, 2006
Start
Dec 2001
Completion
Mar 2002
Last update
Dec 6, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Dec 6, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00290043
Lead sponsor
Sanofi
First posted
Feb 10, 2006
Start date
Dec 2001
Completion
Mar 2002
Last update
Dec 6, 2010

Study contacts

Klaus Rave, Dr.
principal investigator · Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin glulisine

Start the discussion